Skip to Main Content

Kathy High, a scientist and executive who led the development of the first gene therapy approved in the U.S., has left Bayer subsidiary AskBio two years after joining.

An AskBio spokesperson confirmed her departure, adding in an email that High “decided to leave AskBio to begin a sabbatical at Rockefeller University and spend more time with her family, before focusing on ventures in new spaces.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment